NCT01853553View on ClinicalTrials.gov

Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

ADPKD

Interventions

DRUG

Spironolactone

Blood pressure medication.

DRUG

Sugar pill

Placebo.

Trial Locations (1)

80045

UColorado, Aurora

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Colorado, Denver

OTHER

NCT01853553 - Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Biotech Hunter | Biotech Hunter